A human monoclonal antibody that has been studied for the treatment of Alzheimer's disease (AD). The antibody targets aggregated forms of β-amyloid found in the brains of people with Alzheimer’s disease, in the hopes of reducing its build-up.
Used in the early stages of Parkinson's disease which affects release and reuptake of dopamine.
Oral/ intramuscular drug used to treat movement disorders such as dytonia and Parkinson's disease. Benztropine acts as an anticholinergic agent to block cholinergic activity in the basal ganglia.
Used for the adjunctive treatment of all forms of Parkinson's disease: postencephalitic, idiopathic, and arteriosclerotic. Specific mode of action is unknown, but it is thought that this agent partially blocks central (striatal) cholinergic receptors, thereby helping to balance cholinergic and dopaminergic activity.
Bromocriptine is an ergot derivatve that is an anticholinergic. By bloking acetylcholine it helps decrease muscle stiffness, sweating, and the production of saliva, and helps improve walking ability in people with Parkinson's disease.
Is given to people with Parkinson's disease in order to inhibit DOPA decarboxylase. This is an important enzyme which plays a role in the biosynthesis of L-tryptophan to serotonin and in the biosynthesis of L-DOPA to dopamine.
An oral medication give to patients with Alzheimer's disease that aids the cognitive function of those with the disease. Donepezil binds and reversibly inactivates the cholinesterases, thus inhibiting hydrolysis of acetylcholine. This increases acetylcholine concentrations at cholinergic synapses.
Is a neuroprotective agent that is able to slow down the progression of ALS. Edaravone is a strong antioxidant that prevents oxidative stress from motor neuron death in ALS patients, thus slowing down the physical function in patients.
Entacapone, together with levodopa and carbidopa allows levodopa to have a longer effect in the brain and reduces Parkinson’s disease signs and symptoms for a greater length of time. Entacapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). COMT eliminates biologically active catechols present in catecholamines.
Is taken for the treatment of mild to moderate vascular dementia and Alzheimer's disease. Galantamine inhibits acetylcholinesterase, an enzyme which hydrolyzes acetylcholine. As a result of acetylcholinesterase inhibition, galanthamine increases the availability of acetylcholine for synaptic transmission.
Is used in the clinical treatment of Parkinson's disease. Levodopa crosses the blood–brain barrier, whereas dopamine itself cannot. Thus, Levodopa is used to increase dopamine concentrations in the treatment of Parkinson's disease.
Is the first drug to be approved by the FDA in the treatment of ALS. Riluzole preferentially blocks TTX-sensitive sodium channels, which are associated with damaged neurons. Furthermore it protects neurons from glutamate which is theorized to cause nerve damage in ALS patients.
An "off-label" treatment of Huntingtion's disease. Its assumed mechanism of action is that it is able to block dopaminergic and serotonergic receptors in the brain, this leads to reduced tremors in patients with Huntington's disease.
A cholinesterase inhibitor used for the treatment of mild to moderate Alzheimer's disease and Parkinson's disease. Rivastigmine has demonstrated treatment effects on the cognitive, functional, and behavioural problems commonly associated with Alzheimer's disease.
Is the first drug to be approved by the FDA for the treatment of Huntington's disease. Is used to treat chorea which is associated with Huntington's disease. It acts as a reversible high affinity inhibitor of monoamine uptake into vesicles of presynaptic neurons.